Abstract
Introduction
Skeletal muscle is one of the most affected tissues during chronic disuse situations resulting from prolonged bed rest, trauma to the neuromuscular apparatus and microgravity environment. These situations involve both hypokinesia and hypodynamia, thereby reducing neuromuscular activity and directly causing muscle atrophy. The loss of muscle can occur rapidly and significantly within in fact 2 days of disuse onset [1] , and an abundant literature already describes the multitude of muscle adaptations affecting the expression of metabolic, structural and contractile proteins [2] [3] [4] [5] [6] .
To date, our understanding of the effect of hypokinesia and hypodynamia on skeletal muscle is mainly derived from studies that focused on elucidating the specific contributions of transcriptional mechanisms, intracellular signalling molecules and the extent of cross-talks between these various pathways during muscle wasting. The patterns of mRNA changes have been defined in several well-characterized pathological or physiological states that cause muscle wasting, such as disuse-induced, age-related (sarcopenia) and disease-related (cachexia) atrophy [7] . Molecular targets affected in sarcopenia seem to be less related to cachexia and disused-induced atrophy. However, contrary to disuseinduced atrophy, tumour cachexia and sepsis are often associated with increased activation of signalling pathways such as tumour necrosis factor (TNF)-␣. Thus differences in signalling pathways likely exist between these two latter models. 
In parallel to defining the cellular and molecular events controlling the atrophic process, it appears crucial to also identify the best protocols to counteract muscle atrophy. The ultimate goal in this case, is to develop effective and therapeutic exercise paradigms, nutritional supplements, pharmacological agents and/or genetic countermeasures to prevent, limit or even reverse skeletal muscle atrophy. In its first section, this review provides an up-to-date account of atrophy signalling pathways related mainly to chronic disuse, microgravity and unloading. Although phenotypic adaptations during muscle disuse affect a broad spectrum of genes and proteins [6, 8], we focus mostly on events causing the actual loss of muscle mass, and on the main transcription factors currently known to be involved in muscle atrophy, namely nuclear factor B (NF-B) and the Forkhead family of transcription factors (FOXOs). For this, special attention is given to studies using simulated atrophy models in both animals, such as immobilization, hindlimb suspension and denervation, and in human beings, such as immobilization and bed rest, as well as to the contributions of cellular and molecular experimentations. The second section presents several approaches to counteract muscle atrophy and discusses how the different types of countermeasures affect atrophic signalling pathways.

Overview of signalling pathways involved in disuse-induced muscle atrophy
Several pathways contribute to increased protein degradation but to different extents
Different proteolytic systems have been described in skeletal muscle and they have been well reviewed [28] . In this context, chronic disuse leads to activation of the different proteolytic systems, mainly the calpain (Fig. 1B1), lysosomal (Fig. 1B2 ) and ubiquitinproteasome systems (Fig. 1B3) [47, 48] .
The ubiquitin-proteasome complex has been largely studied and appears to catalyse the majority of protein breakdown in mammalian cells. It is therefore not surprising that this system significantly contributes to the control of muscle mass [49] . In this system, degradation of proteins requires hydrolysis of adenosine triphosphate (ATP), the protein co-factor ubiquitin and the 26S proteasome [50] [51] .
A number of studies have now shown that the ubiquitin-proteasome system is necessary for most of the increase in proteolysis during inactivity [52] , cachexia [53] and diabetic atrophy [49] . More specifically, several mRNAs encoding proteins involved in the ubiquitin-proteasome pathway are increased in muscle atrophy highlighting the key role of this system in controlling protein degradation following either hindlimb unloading [54, 55] , spaceflight [32] and denervation [56] .
In skeletal muscle undergoing disuse atrophy, two specific E3 ligases were identified some time ago. Indeed, two groups simultaneously described MAFbx/atrogin1 [57, 58] , and a ring fingercontaining ligase called MURF1 [58, 59] . Additionally, two others E3s have been described, namely Nedd4 [60] , whose expression is increased after 14 days of unloading [61] and after 1 and 3 months of denervation [62] , and E3␣, also known as Ubr1 [63] which acts together with the ubiquitin carrier protein E214k. The role of these ligases has been highlighted in atrophying muscles from tumour-bearing or septic rats in which E3␣/Ubr1 inhibitors reduce the accelerated rate of ubiquitin conjugation [64] . However [59] . However, no differences in the level of these proteins were reported between MURF Ϫ/Ϫ and control mice [67, 68] . Only troponin I [68] and myosin heavy chain [69] [70] .
MAFbx/atrogin1 contains a F-box domain allowing targeting of protein substrates for ubiquination and degradation. MyoD [71] 
On the left, the Akt/FOXO transcriptional control pathway is shown leading to the induction of atrogenes (ubiquitin ligases). On the right, a specific NF-B pathway is activated during disuse atrophy. (C) Apoptotic pathways are also shown as they represent additional events controlling muscle atrophy. (C1) and (C2) highlight apoptosis induced in a caspase-dependent versus caspase-independent manner, respectively. (D) Myostatin pathway. Myostatin, growth differentiation factor-8 (GDF8), a member of the TGF-␤, is a negative regulator of muscle mass acting via Smad transcription factors. See text in first section for details.
as well as calcineurin [72] [74] and/or that some proteasome degradation occurs in nuclei as showed previously for MyoD degradation [75] .
Akt/FOXO transcriptional control and induction of the ubiquitin ligase pathway
Akt has multiple functions. Although Akt2 is mainly involved in glucose metabolism [76] , Akt1, acts as a nodal point (see Fig. 1 [81, 82] . In addition, FOXO1 activity has been shown to be required for MAFbx/atrogin1 [81] and indirectly for MURF1 [83] induction whereas FOXO3a activity has been shown to induce transcriptional regulation of MAFbx/atrogin1 [81, 84] and MURF1 [84] . Interestingly, the study of Mammucari et al. demonstrated that FOXO3a also controls the activation of the autophagic/lysosomal pathway in fasting and denervation models of atrophy [48] . Together, these data strongly support the notion that FOXO transcription factors play a direct role in the progression of muscle disuse atrophy and highlight that common transcription factors, like FOXO3, could regulate muscle atrophy via the proteasome and lysosomal system in a coordinated manner.
NF-B Pathways activated during disuse atrophy The NF-B represents a family (Rel) of five transcription factors (p65, Rel B, c-Rel, p52 and p50) ubiquitously expressed and involved in a multitude of processes such as immune and inflammatory responses, cell survival and cell adhesion [85]. NF-B is a mediator of the effects of cytokine TNF-␣ during inflammation. In cachexia, characterized by an accelerated loss of muscle mass due to a chronic inflammatory response, p65/p50 heterodimers are activated and are considered as the canonic mode of activation. Briefly, the major upstream activators in this case are circulating cytokines, especially TNF-␣ (first identified as 'cachectin'), which induce phosphorylation of NF-B inhibitor protein (I-kB␣) by activating the IKK kinase. Upon phosphorylation, I-kB␣ becomes polyubiquitinated and degraded by the proteasome thereby enabling NF-B nuclear translocation and transcriptional activation.
Disuse atrophy has also been shown to activate NF-B [86, 87] . Because in disuse atrophy, there is no evidence of enhanced TNF-␣ production or other inflammatory cytokines [88] , it appears that the trigger for NF-B activation is independent of these cytokines leading to the idea that a specific NF-B pathway is activated during unloading atrophy instead of the more classical pathway acting via TNF-␣ [88, 89] . This alternative pathway of NF-B activation has been partly elucidated and shown to require p50 and Bcl-3 but not p65 (Fig. 1B, right) [95] . Several studies dealing with muscle hypertrophy using overload as an experimental model in animals [96, 97] [99] or human beings [100] , and following hindlimb suspension [101] or chronic denervation in rats [102] [107, 108] . Apoptosis is an evolutionary conserved cell-suicide program essential for embryogenesis, development and maintenance of tissue homeostasis. In skeletal muscle, apoptosis has also been shown to contribute to sarcopenia and cachexia [109] . In disuse-induced atrophy, chromatin condensation and DNA fragmentation has been observed [103, 110] [111] . Mitochondria play a major role in regulating apoptosis via their ability to release cytochrome c into the cytosol (Fig. 1C) [111] (Fig. 1C1) . These cysteine-dependent aspartate-specific proteases are normally found in the cytoplasm in an inactive procaspase state. However, these procaspases can be readily activated upon proteolytic cleavage [114] [116] . The authors suggest that other proteases are required to disassemble the myofibril for the 26S proteasome and that caspase 3 regulates denervation induced signalling via the mitochondrial associated apoptotic pathway [116] .
Apoptosis has been observed following denervation [108] and hindlimb suspension [107, 117] [118] , but an increase in caspase 8 activity has been reported with the same model of atrophy [117] . Thus, these data clearly suggest that the involvement of caspases in apoptotic events in atrophying muscle may depend on the selected experimental models. In this regard, apoptosis induced in a caspase-independent manner has been investigated in disuse-induced muscle atrophy (Fig. 1C2) . In this case, mitochondria can release other pro-apoptotic proteins such as apoptosis-inducing factor (AIF) [119] and endonuclease G (EndoG) which can translocate to nuclei where they induce DNA fragmentation leading to apoptosis [120] . Of particular relevance is the observations of Dupont-Versteegden et al. who showed a lack of activation of caspase 3, 7 and 12, and a marked accumulation of EndoG to myonuclei following hindlimb suspension [118] .
In [121, 122] (Fig. 1D) . Thus, a number of investigations have been conducted in the last 10 years in order to understand the potential involvement of myostatin in muscle growth and regeneration. In human beings, the first natural myostatin mutation was recently identified in a child who showed a very similar phenotype to the myostatindeficient mouse [123] . Knockout of the myostatin gene in mice induces a dramatic increase in muscle mass resulting from a combination of hyperplasia, hypertrophy [121] . [124, 125] . In cattle, mutation of this gene results in a 'doubled-muscled' phenotype associated almost exclusively with fibre hyperplasia [126, 127] [129, 130] . [131, 132] .
Preferential role of myostatin in inhibiting hypertrophy rather than inducing atrophy Myostatin (growth differentiation factor-8, GDF8), a member of the transforming growth factor-␤ (TGF-␤), is a negative regulator of muscle mass acting via Smad transcription factors
In adult mice, inhibition of myostatin activity using injections of an anti-myostatin antibody for 4 days leads to an increase phosphorylation of p70S6 kinase and ribosomal protein S6 and demonstrates that myostatin exerts a tonic inhibitory influence on the rate of myofibrillar protein synthesis
, underlining different patterns of myostatin expression and distinct temporal roles for this factor during embryogenesis in various species. By contrast, over-expression of myostatin has been shown to cause significant loss in muscle mass in mice, an effect reversible by follistatin administration [128]. During skeletal muscle development, it has been shown that myostatin overexpression inhibits myoblast proliferation, differentiation, and apoptosis
The group of Freyssenet reported recently that myostatin may also contribute to the regulation of skeletal muscle mass in adulthood by showing that myostatin overexpression induced a marked downregulation of Akt/mTOR signalling pathway but failed to increase expression of atrogenes (MURF1, MAFbx, Nedd4 and ZNF216) and regulate the catalytic activities of the proteasome
Follistatin, an extracellular factor that binds and modulates activin, interacts with and inhibits the activity of several TGF-␤ family members [133] . Follistatin interacts directly with myostatin to inhibit its activity resulting in an increase in muscle mass [134, 135] . Thus, it has been reported that mice overexpressing follistatin display a very similar muscle phenotype of that seen in the absence of myostatin [135] . In disuse atrophy, follistatin mRNA levels have been shown to be highly induced in animal models [26] , following long term bed rest in human beings [33] , as well as during sarcopenia [136] . [137] and 10 days of hindlimb suspension [138] , indicating a preferential role for myostatin in fast fibre type. However, others failed to detect any change in its expression following 7 days of hindlimb suspension in different muscle types [139] and following four to 14 days of immobilization in fast type human muscles [140, 141] . Given that myostatin expression decreases with exercise [140, 142] [144] . Furthermore, the expected increase in FOXO3a mRNA following dexamethasone-induced atrophy was abolished in myostatin-deficient mice [145] . These new findings are important as they seem to link myostatin to the atrophic pathways in specific cases of atrophy.
The role of myostatin in atrophy remains nebulous and conflicting results have been reported. Several studies have shown an increase in myostatin expression in fast type muscles in rodents following 17 days of microgravity
Different approaches to counteract muscle disuse-induced atrophy
A practical perspective when dealing with disuse atrophy is to identify adequate prescription in order to counteract the negative impact on human health and performance of such conditions as chronic inactivity, long-term spaceflight or aging. Preventive medicine, therapeutic intervention, clinical care and rehabilitation programs have together used a variety of approaches in attempts to prevent and reverse atrophy. These varied approaches are referred to as 'countermeasures'. Together with on-going efforts aimed at deciphering the cellular and molecular basis of muscle disuseatrophy, it seems critical to concomitantly identify appropriate countermeasures and define their impact not only on the extent of muscle mass reduction but also, on the various signalling pathways and biomarkers triggered during the atrophic process. The ultimate goal is to develop effective countermeasures to prevent, limit or even reverse skeletal muscle atrophy and functional loss in response to reduced activity on earth, exposure to microgravity environment or following disease/injury. Although many varied approaches are being investigated, these can basically be grouped into three distinct classes: exercise and physical training, nutritional aids and manipulations of growth factors.
Exercise and physical training
Among the different types of available countermeasures, physical exercise with high resistance loading appears efficient to counteract the deficits in muscle structure and function during human bed rest [146, 147] and hindlimb suspension in animal models [148, 149] [2] . [150] or 14 days of bed rest in human beings [151] . Maximal resistance exercise, during limb unloading, also counteracts the deficits normally seen in total RNA, total mRNA and actin and myosin heavy chain mRNA levels following disuse atrophy [152] . At [156] while preserving single muscle fibre function [157] and fibre size, and preventing the slow to fast phenotype switch [157, 158] [159] . Under many different conditions, exercise cannot always be used as unique countermeasures. Therefore, other strategies have been studied in order to counteract or prevent catabolic processes during chronic disuse.
. Together with previous studies dealing with mechanical and physiological parameters, this body of work has led to the notion that the most efficient exercise program should include isometric and isotonic (concentric and eccentric) exercises as well as highintensity exercises. A more marked positive effect of exercise has been described during the early phases of atrophy (until 7 days) which may be related to the prevention of decreased protein synthesis during the early phase compared to reducing degradation which becomes more prevalent at later time-points
Although the beneficial effects of exercise to counteract dis-
Nutritional aids
During bed rest, whole body protein turnover is mainly reflected by muscle protein turnover leading to a loss of lean body mass [20]. The reduction in protein synthesis is much greater (up to 45%) during long duration spaceflight [21]. This loss can be amplified by an increased level of circulating cortisol induced by the accompanying stress
One of preferred approaches for nutritional aid consists of amino acid supplementation [160] . Amino acids are generally well recognized for their anabolic effects [161] and ability to stimulate protein synthesis in skeletal muscle [162, 163] . In this context, it is known that amino acids primarily exert their effects on protein synthesis by accelerating peptide chain initiation rather than elongation [164] . Among essential amino acids, leucine appears to mediate most of the effects of protein/amino acid intake on protein metabolism and is well recognized as an anabolic factor [165] . The specific mechanisms by which leucine exerts its potent effects on protein synthesis and degradation remain, however, unclear. Work by Anthony et al. showed that leucine had a stimulatory effect on the assembly of the eIF4F complex, a key component in the mRNA binding step in translation initiation [166] . Similarly, Carroll et al. also showed that amino acid administration can elevate fractional synthesis rate in the soleus muscle leading to the idea that slow muscle may be more dependent on nutritional status than on exercise [167] . Although several studies have reported a major role for leucine in protein synthesis through PI3K and mTOR signalling pathways in vivo [168] and in vitro [169, 170] , further studies should evaluate the effects of essential amino acids on signalling pathways involved in disuse muscle atrophy.
Although amino acid supplementation can promote protein synthesis during the atrophy process, there are data indicating that it can also be beneficial by reducing proteolytic events. In this context, a study of Nakashima et al. is relevant because these authors showed that leucine supplementation inhibits ubiquitin and proteasome C2 subunit mRNA expression in chick myotubes and skeletal muscles, while also inhibiting expression of the mcalpain large subunit [171] . These findings indicate that leucine has the ability to suppress the ubiquitin-proteasome proteolytic pathway and degradation of myofibrillar proteins.
In contrast to the findings described above, recent study on women muscle showed that dietary protein supplementation during long-term bed rest with enrichment of leucine intake, failed to counteract the decrease in isometric and dynamic muscle strength [156] , changes in single muscle fibre function [157] , alterations in fibre size as well as the slow to fast phenotype transition [157, 158] . The modest impact of protein supplementation on the atrophic process was also described systematically by using a transcriptomics approach. Through this approach, it was shown that only 25% to 40% of the number of differentially expressed mRNAs induced by 60 days of bed rest was normalized by protein supplementation, including several mRNAS coding for proteins regulating degradation pathways [33] . [172] . All members of the IGF-1, FGF and TGF-␤ family promote proliferation of satellite cells whereas myogenic differentiation is mainly driven by IGFs [173] . Several growth factors have been tested in attempts to attenuate or reverse muscle atrophy but the degree of success appears to largely depend on the specific actions of the growth factor studied, method of delivery and model of atrophy.
Manipulations of growth factors
Signalling transduction pathways initiated by growth factors such as IGF-1, fibroblast growth factor (FGF) and TGF-␤, exert a profound influence over muscle gene expression. In particular, a number of growth factors contribute to the regulation of satellite cell proliferation, differentiation and motility
IGF-I, originally named somatomedin, was described as the factor by which the growth hormone (GH) exerted its anabolic actions in most tissues [174] . [81, 83] . Thus, IGF-1/PI3K/Akt signalling is sufficient to induce hypertrophy via activation of protein synthesis pathways while concurrently suppressing activation of denervation-or dexamethasone-induced atrophy pathways [22] . The anabolic activity of IGF-I as an endocrine, circulating hormone produced by the liver, is clearly distinct from its activity as an autocrine/paracrine growth factor locally secreted [175] . Hence, it appears rather clear that IGF-I administration, resulting in higher levels of serum IGF-I, plays a role in the development and maintenance of muscle mass only in cases of GH deficiency, and not in healthy persons [176] . By contrast, locally produced, autocrine/paracrine IGF-I, has been shown to play a significant role in pre-and post-natal muscle growth. The hypertrophic effects of GH are mediated in this case by locally produced IGF-I [177] . In this context, it has been shown that muscle specific expression of IGF-1, via local injection of IGF-I expression construct followed by electroporation 3 days before unloading, is an effective inhibitor of muscle atrophy [178] .
The complex regulatory system of IGFs comprises two IGFs (IGF-I and IGF-II), cell surface receptors (types I and II), six specific high-affinity binding proteins (IGFBP1-6), IGFBP proteases and others IGFBP-interacting molecules. The importance of IGFs in growth and development is well established. As described in first section, the IGF-1/PI3K/Akt signalling is able to suppress the activation of atrophy pathways by suppressing catabolic events associated with MAFbx and MURF1
FGFs are stored in the extracellular matrix where they bind proteoheparan sulphates until used for local actions. Their biological cellular effects are initiated via high affinity tyrosine kinase (FGFRs) and low affinity heparin sulphate proteoglycan cell surface receptors [179] . The FGFs are involved in foetal skeletal muscle growth and development as well as in the development of cultured myogenic cells in vitro where they act as strong regulators of myoblast proliferation [179, 180] . Thus, treatment of cultured myoblasts with these factors stimulates proliferation and represses terminal differentiation. FGFR1, a receptor for several members of the FGF family highly expressed in adult skeletal muscle, has been used to counteract disuse atrophy. By electroporation of plasmid DNA into mice hindlimb muscles 2 days before 7 or 14 days of hindlimb suspension, it was shown that ectopic expression of FGFR1 stimulates protein synthesis and inhibits muscle atrophy [180] 
. However, although the role of FGFs in regulation of myoblast proliferation and differentiation has been clearly demonstrated, a definitive role for this family of growth factors in mature fibre maintenance, in regulating hypertrophy and/or in counteracting atrophy awaits further experimentation.
TGF-␤ is the prototypical family member of the cytokine family, and has a broad spectrum of effects ranging from proliferation, differentiation, adhesion, migration, apoptosis and regulation of cell growth [181] . In skeletal muscle, TGF-␤ has been shown to be involved in muscle development and maintenance of post-natal muscle mass. Generally, members of the TGF-␤ family inhibit muscle proliferation and differentiation by silencing the transcriptional activation of myogenic regulatory factors such as MyoD [182] . Among the large number of TGF-␤ superfamily members, myostatin has been shown to be expressed in skeletal muscle, heart and adipose tissue [183] . As mentioned previously, myostatin is known to act as an inhibitor of muscle mass growth. Blockade of myostatin, by a pharmacological approach consisting of the administration of an anti-myostatin monoclonal antibody to inhibit the binding of myostatin to its receptor ActRIIB, has been shown to result in growth of dystrophic muscles [184] . Moreover, another study showed that blockade of myostatin using myostatin knockout mice, harbouring a deletion of the third myostatin exon, could prevent glucocorticoid-induced muscle atrophy [145] [139] . In fact, the extent of atrophy for some muscles was even greater in mice deficient in myostatin (Table 1) [139] . Although the loss of myostatin activity improves muscle mass and regeneration in dystrophic muscles, it seems that its effects in atrophying muscles are controversial. Thus, the use of myostatin as a target for counteracting skeletal muscle disuse atrophy remains to be further explored [184] . 185, 186] . The peak of oxidant activity has been observed at day 3 of hindlimb suspension in mice and persists for up to 12 days [187] . Whereas allopurinol administration (50 mg/kg/day), a xanthine oxidase inhibitor with antioxidant properties, was not able to counteract muscle atrophy of hindlimb suspended mice [188] , diet supplementation with 1% Bowman-Birk inhibitor concentrate (BBI/C) during 12 days hindlimb unloading was shown to have beneficial effects [187] . BBI, a soy protein, widely recognized as a serine protease inhibitor, is able to decrease matrix metalloproteinase activity but not that of the proteasome [187] . As an antioxidant, BBIC was able to depress cytosolic oxidant activity, without quenching nitric oxide release in unloaded soleus muscle, thereby offering some protection [187] [189, 190] [191] . Importantly, these findings show that NF-B inhibition alone is not sufficient to prevent skeletal muscle atrophy. ␤-2-adrenergic agonists have also been examined for their ability to prevent muscle atrophy. Even though the mechanisms of action remain unclear, clenbuterol (CB), a ␤-2-adrenergic agonist with growth-promoting properties, can stimulate increases in muscle mass [192] while reducing the extent of muscle atrophy following hindlimb suspension [193] or denervation via activation of the ␤-2-adrenergic receptor [194] . Additional [196] . These previous results generally come from global training experiments in young and older athletes [197, 198] or in elderly persons to counteract sarcopenia [196] . Whey/milk protein supplementation, containing high levels of leucine, has been described to be advantageous for gaining muscle size and improving muscle protein balance after a resistance exercise bout [199] . Although these studies did not examine conditions of muscle atrophy, they nonetheless bring important information on the synergistic effects of resistance exercise and amino acid supplementation upon muscle contraction-induced augmentation of protein synthesis, when supplementation is provided either intravenously [162] or orally [200] . Interestingly, timing of the nutrient intake appears as a crucial parameter. Indeed, it has been well demonstrated that nutrient intake before and/or immediately after a resistance exercise session is more beneficial in terms of muscle protein anabolism [201] . Recently, an increase in the cell cycle kinase cdk2 mRNA expression was reported following 21 days of resistance exercise with protein supplementation, ingested immediately before and after each bout of RE, thereby suggesting a higher proliferating cell activation response [202] . These authors hypothesized, taking into account that leucine activates myogenic satellite cells through the mTOR pathway [203] , that an increase in satellite cell proliferation had occurred following resistance exercise training when protein supplementation is ingested closely to the exercise session [202] .
Additional nutritional, ergogenic supplements and drugs
. Dietary curcumin (1% supplementation) was not able to inhibit the activation of NF-B during unloading-induced atrophy and the accompanying weakness, whereas dietary NAC (1% supplementation in water) could prevent the activation of NF-B but not muscle atrophy and weakness
A number of studies have attempted to increase muscle adaptations to resistance training by increasing levels of IGF-I. In this context, IGF-I locally produced has been shown to play a much more important role in muscle growth and bring better results than IGF-1 alone [150] . Experiments using combined and locally applied GH/IGF-1 treatment, immediately before each maximal resistance exercise showed a more positive effect on muscle atrophy and apoptosis associated with hindlimb unloading in animals [101, 204] . More recently, a combination of resistance training and injection into muscle of an adenoviral vector encoding IGF-I led to increases in muscle mass and force production compared to exercise alone [205] . On the other hand, increasing levels of circulating IGF-I, together with exercise training, has failed to induce further benefits in elderly men or young persons performing resistance exercise training [206, 207] .
In human bed rest studies, exercise countermeasures have also been combined to additional physical or mechanical stimulation, like penguin suit [208] , artificial gravity using a human-powered short-arm centrifuge [209] or vibration [210, 211] 
